Delcath Systems Inc(DCTH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 2590.16 | EPS (ttm) | 0.01 | Insider Own | 7.47% | Shs Outstand | 34.6M | Perf Week | -4.7% |
| Market Cap | 0.55B | Forward P/E | - | EPS next Y | 67.2% | Insider Trans | - | Shs Float | 32.1M | Perf Month | -8.25% |
| Enterprise Value | 0.45B | PEG | - | EPS next Q | -0.09 | Inst Own | 50.43% | Short Float | 7.33% | Perf Quarter | 41.2% |
| Income | 0.00B | P/S | 5.75 | EPS this Y | -357.14% | Inst Trans | 5.3% | Short Ratio | 4.45 | Perf Half Y | 63.22% |
| Sales | 0.10B | P/B | 4.52 | EPS next 5Y | 37% | ROA | 0.42% | Short Interest | 2.36M | Perf YTD | 56.44% |
| Book/sh | 3.5 | P/C | 5.72 | EPS past 3/5Y | - | ROE | 0.47% | 52W High | -9.3% ($17.42) | Perf Year | 42.09% |
| Cash/sh | 2.76 | P/FCF | 31.31 | Sales past 3/5Y | 215.3% 120.21% | ROIC | 0.43% | 52W Low | 94.58% ($8.12) | Perf 3Y | 228.48% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -76.27% | Gross Margin | 87.05% | Volatility(W/M) | 2.4% 2.93% | Perf 5Y | 52.66% |
| Dividend TTM | - | EV/Sales | 4.77 | Sales Y/Y TTM | 35.85% | Oper. Margin | -1.9% | ATR (14) | 0.53 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 8.95 | EPS Q/Q | 0.15% | Profit Margin | 0.56% | RSI (14) | 49.64 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.83 | Sales Q/Q | 20.6% | SMA20 | -4.85% ($16.61) | Beta | 0.6 | Target Price | $24.5 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/6 | SMA50 | 7.94% ($14.64) | Rel Volume | 0.57 | Prev Close | $15.98 |
| Employees | 156 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 178.56% 10.97% | SMA200 | 38.91% ($11.37) | Avg Volume(3M) | 0.53M | Price | $15.8 |
| IPO | 2001/10/23 | Option/Short | Yes/Yes | Trades | 4832 | Volume | 303,583 | Change | -1.13% |
Company
DCTH is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩺 Delcath Systems (DCTH) is an interventional oncology medical device company focused on the treatment of primary and metastatic liver cancer. Through its flagship products, the HEPZATO KIT and CHEMOSAT, the company provides a treatment system that delivers high-dose chemotherapy locally to the liver while controlling systemic exposure.
Over the past 1 year, on the higher side
9% below its 1-year high.
DCTH has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -357.1% this year.
Tap to view numbers
The price looks about right
Trading at 2590.2 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +228.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 50.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SURI 0.04%
FOXY 0.01%
SBAR 0.01%
SBIO 0.00%
IWC 0.00%It ranks #4 in the industry
Based on market cap of $548M.
DCTH $548M PER 2590.2
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is DCTH?
DCTH belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of DCTH?
The market cap of DCTH is approximately $548M, ranking 3,158 within its sector.
What is the P/E ratio of DCTH?
DCTH has a P/E ratio of approximately 2590.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for DCTH?
DCTH has recorded a 52-week high of $17.42 and a low of $8.12.
